Use of cardiovascular drugs in pregnancy
Halawa, B.
Wiadomosci Lekarskie 42(2): 94-100
1989
ISSN/ISBN: 0043-5147 PMID: 2683387 Document Number: 333375
Document emailed within 1 workday
Related Documents
Panicker, G.K.; Karnad, D.R.; Salvi, V.; Kothari, S. 2012: Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs Journal of the Association of Physicians of India 60: 56-61Bangalee, V; Suleman, F 2016: Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa? Health Sa Gesondheid 21: 60-66
Yanaginuma, T. 1984: Clinical pharmacology for midwives. 3. Pregnancy and drugs. 3. Drugs with their risk superseding the benefits Josanpu Zasshi 38(6): 526-530
Takayanagi, M. 1985: Pregnancy and drugs: are all drugs harmful to the fetus? Josanpu Zasshi 39(12): 1069-1074
Arushanian, E.B. 2000: Chronopharmacology of cardiovascular drugs Eksperimental'naia i Klinicheskaia Farmakologiia 63(6): 67-75
Marcus, F.I. 1996: Titrating cardiovascular drugs Clinical Chemistry 42(8 Pt 2): 1312-1315
Eto, M. 2011: Cardiovascular drugs and cognitive impairment Nihon Rinsho. Japanese Journal of Clinical Medicine 69 Suppl 10 Pt 2: 166-169
Bretagne, J.F.; Gastard, J. 1987: Portal hypertension and cardiovascular drugs Annales de Gastroenterologie et d'Hepatologie 23(2): 75-81
Stazi, C.; Stazi, F. 1991: The cardiovascular system and antidepressive drugs La Clinica Terapeutica 137(2): 125-135
Campbell, A.W. 2014: Cardiovascular disease and statin drugs Alternative Therapies in Health and Medicine 20(5): 8-9
Ivleva, A.I. 2006: Investigation of efficacy of cardiovascular drugs in women Kardiologiia 46(3): 85-89
Iarussi, D.; Gualtieri, S.; Tedesco, M.A.; Iacono, A. 1995: Cardiovascular toxic effects of drugs not used in cardiology Cardiologia 40(12 Suppl 1: 105-111
Anibaldi, A.; Santin, L.; Scalercio, A.; Stella, S. 1982: Toxic effects of drugs on the cardiovascular system Minerva Pediatrica 34(5): 215-224
Reznikov, K.M. 1981: Changes in the toxicity of certain cardiovascular drugs as a result of hyperbaric oxygenation Farmakologiia i Toksikologiia 44(3): 342-346
Robertson, J.I. 1991: Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs Journal of Cardiovascular Pharmacology 17(Suppl 5): S48-S53
Alušík, Štefan.; Paluch, Zoltán. 2018: Cardiovascular risk of non-steroidal anti-inflammatory drugs Vnitrni Lekarstvi 64(3): 266-271
Biamino, G.; Fenner, H.; Schüren, K.P.; Neye, J.; Ramdohr, B.; Lohmann, R.W. 1975: Cardiovascular side effects of tricyclic antidepressants - a risk in the use of these drugs International Journal of Clinical Pharmacology and Biopharmacy 11(3): 253-261
Fretheim, A.; Bjørndal, A.; Oxman, A.D.; Dyrdal, A.; Golding, M.; Ose, L.; Reikvam, A.; Teisberg, P. 2002: Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 122(23): 2287-2288
Halawa, B. 1981: Complications associated with sudden withdrawal of various drugs used in the treatment of cardiovascular diseases Wiadomosci Lekarskie 34(6): 491-495
Janků, K.; Srp, B. 1993: Serious cardiovascular diseases in pregnancy Ceskoslovenska Gynekologie 58 Suppl: 38-43